Overview

Phase II Study Using Thalidomide for the Treatment of ALS

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The use of Thalidomide in patients with ALS who have disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborator:
Celgene Corporation
Treatments:
Thalidomide